Vincent Procaccio – Head of the Department of Genetics at Angers University Hospital, joins KetoM+
His remarkable professional skills and personality will be a great addition to our team and a critical asset for the... View Article
Pherecydes Pharma obtains ANSM approval for its PhagoDAIR program, the world’s first study in precision phage therapy
PhagoDAIR is a phase I/II clinical study with anti-Staphylococcus aureus phages in the treatment of osteoarticular infections of prostheses caused... View Article
Valneva announces positive lot-to-lot consistency trial results for its single-shot Chikungunya vaccine candidate
Valneva, a specialty vaccine company, announced positive topline results from the lot-to-lot Phase 3 trial of its single-shot chikungunya vaccine... View Article
Four projects involving members of the cluster, winners of the call for research proposals “Recherche Hospitalo-Universitaire en santé” (RHU)
Four projects involving members of the cluster, winners of the call for research proposals “Recherche Hospitalo-Universitaire en santé” (RHU) Olivier... View Article
Valneva announces positive homologous booster data for inactivated, adjuvanted COVID-19 vaccine candidate VLA
Initial results show excellent immune response after third dose of VLA2001 administered 7 to 8 months after the second dose... View Article
Pherecydes Pharma continues to strengthen its intellectual property with a first patent granted in China
Pherecydes Pharma, a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, announced the granting... View Article
New member | AbolerIS Pharma
AbolerIS Pharma aims to develop novel and unique therapeutic approaches to induce immune tolerance and preserves useful immune responses in... View Article
New member | THERADEV
THERADEV develops solutions composed of phytogenic active ingredients for the prevention of metabolic diseases. Find out more about THERADEV: www.theradev.fr
New member | Theradev
Theradev specialises in the research and development of innovative solutions for the regulation of major metabolic disorders. Thanks to its... View Article
ABYS® MEDICAL successfully completes its first Series A of €3 million
Abys® Medical, deeptech creator of the Surgery 4.0 concept, finalized in August 2021 a fundraising by opening its capital to... View Article